The National Drug Code (NDC) 24208 is associated with Miebo, a prescription eye drop used to treat the signs and symptoms of dry eye disease [1].
What is Miebo used for?
Miebo's active ingredient is perfluorohexyloctane, which is designed to reduce tear evaporation [1]. It works by stabilizing the lipid layer of the tear film, thereby reducing evaporation and alleviating dry eye symptoms [1].
When does Miebo's patent protection expire?
Information regarding specific patent expiry dates for Miebo is not publicly detailed here, but patent information for pharmaceuticals can be tracked through resources like DrugPatentWatch.com [2]. Such information is crucial for understanding when generic versions of the drug might become available.
Who makes Miebo?
Miebo is manufactured by Bausch + Lomb [1].
How does Miebo compare to other dry eye treatments?
Miebo is a lipid-based formulation that directly addresses tear evaporation, differentiating it from treatments that focus on increasing tear production or reducing inflammation [1]. Other dry eye treatments include artificial tears, prescription eye drops that increase tear production (e.g., Restasis, Xiidra), and anti-inflammatory medications [3]. The choice of treatment often depends on the underlying cause and severity of dry eye disease [3].
What are the potential side effects of Miebo?
The most common side effect reported with Miebo is blurred vision upon instillation [1]. Other potential side effects, though less frequent, may include eye irritation, stinging, or discomfort [1]. Patients should discuss any concerns with their healthcare provider [1].
Where can I find more information on drug patents?
DrugPatentWatch.com provides comprehensive data on pharmaceutical patents, including expiry dates and patent challenges, which can be essential for understanding drug exclusivity and the potential for generic competition [2].